News | October 16, 2008

EPIC Carotid Stent Trial Reveals Low Stroke Rate

October 16, 2008 - Lumen Biomedical Inc. said that Principal Investigator Subbarao V. Myla, M.D., presented the results from the EPIC clinical trial — “Evaluating the Use of the FiberNet Embolic Protection System in Carotid Artery Stenting” — at TCT 2008.

From March 2007 to May 2008, the multicenter, single-arm EPIC clinical trial evaluated the FiberNet Embolic Protection System during carotid artery stenting of 237 high surgical risk patients with a critical carotid artery stenosis. The EPIC trial was an FDA IDE clinical study sponsored by Lumen Biomedical Inc.

“EPIC’s superior results stand alone; FiberNet EPS embodies all three successful requirements for safe carotid stenting, low profile, optimal filtration and ease of use,” Dr. Myla said. “The FiberNet System represents the best blend of science and clinical practice finding the right balance of optimal filtration with maintained safe perfusion.”

The FiberNet EPS captures particles released during the carotid artery stenting procedure with a filter made of a 3-dimensional matrix of fibers. The filter is designed to prevent microscopic debris from traveling to the brain. After the particles have been captured, the FiberNet filter is then retrieved into the retrieval catheter, Lumen Biomedical’s FDA-cleared Xtract Aspiration Catheter, and removed from the patient.

The mean age of the patients participating in the clinical trial was 74 years (21 percent were octagenarians), 64 percent male and 20 percent were symptomatic.

Overall, the combined major adverse event rate at 30 days for all death, stroke and myocardial infarction (MI) was 3 percent. There were 5 strokes (4 ischemic and 1 hemorrhagic) for a 30-day stroke rate of 2.1 percent. There were no unanticipated adverse device effects. The results demonstrate that FiberNet EPS' unique features may contribute to a lower stroke rate during carotid artery stenting in high surgical risk patients.

For more information:

Related Content

FDA clears Claret Medical Sentinel embolic protection device for TAVR
Feature | Heart Valve Technology| June 09, 2017
June 5, 2017 – The U.S.
Contego Medical Receives CE Mark for Vanguard IEP Peripheral Balloon Angioplasty System
News | Peripheral Artery Disease (PAD)| May 17, 2017
Contego Medical LLC announced recently that it has received CE Marking of its Vanguard IEP Peripheral Balloon...
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices| April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Cardiogard embolic protection system for surgical valve reaplacement

The CardioGard embolic protection system for surgical aortic valve replacement.

Feature | Embolic Protection Devices| March 22, 2017
March 22, 2017 — Two U.S.
InspireMD, CGuard embolic protection system, EPS, clinical data, internal carotid artery stenosis, ICA
News | Stents Carotid| November 18, 2016
November 18, 2016 — InspireMD Inc.
Sponsored Content | Videos | Heart Valve Technology| November 08, 2016
Studies have shown transcatheter aortic valve replacement (TAVR) has an increased risk of stroke and cerebral damage
TAVR, post-procedure, brain lesions, delirium, TCT 2016, Peter R. Stella
News | Heart Valve Technology| November 07, 2016
Keystone Heart Ltd. announced that data presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2016...
Sentinel, TAVR, TAVI, embloic protection
News | Heart Valve Technology| November 07, 2016
November 7, 2016 – A multicenter randomized trial evaluating the role of embolic protection using the Sentinel device
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices| September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Overlay Init